Work

Abstract AS27: VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase 1 data by the gynecologic oncology group

Year: 2015

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.ovcasymp14-as27

Authors: Bradley J. Monk, William E. Brady, Heather A. Lankes, Andrea Facciabene, Kristi L. Manjarrez, Robert M. Hershberg, Paula M. Fracasso, Katherine M. Bell-McGuinn, Joan L. Walker, Carolyn K. McCourt, Carol Aghajanian, George Coukos

Institutions: St. Joseph's Hospital and Medical Center, Roswell Park Comprehensive Cancer Center, University of Pennsylvania, University of Virginia, Memorial Sloan Kettering Cancer Center, University of Oklahoma Health Sciences Center, Women & Infants Hospital of Rhode Island

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2265046617

Cites:

Cited by: 1

Related to: 10